Optometric Education Consultants
  • About OEC
  • Case Challenge
  • Conferences
    • Scottsdale ’26
    • Pittsburgh ’26
    • Sarasota ’26
    • Amsterdam ’26
    • Disney Resort ’26
    • Quebec ’26
    • Nashville ’26
    • Detroit Recap
    • All Conference Recaps
  • Webinars
  • Recorded Webinars
    Asynchronous
  • YouTube & Resources
Select Page

TQ Quiz | Roadmap to Medical Management of Glaucoma (Pittsburgh 2025)

by Events@optometricedu.com | Feb 16, 2025 | 2025 Pittsburgh, TQ Courses | 0 comments

"*" indicates required fields

This field is hidden when viewing the form

@{:35}

This field is hidden when viewing the form
MM slash DD slash YYYY
This field is hidden when viewing the form
MM slash DD slash YYYY
This field is hidden when viewing the form
MM slash DD slash YYYY
This field is hidden when viewing the form
1. Prior to 2018, the last year that a new glaucoma medication was introduced that had a new Mechanism of Action (MOA) was?*
2. Where is the aqueous humor produced?*
3. What is the primary (highest percentage) pathway for aqueous humor to exit the eye?*
4. The trabecular meshwork consists of how many distinct layers?*
5. Netarsudil appears to also act on the uveoscleral outflow pathway and can lower IOP in the ___?*
6. Which of the following medications is classified as an alpha agonist?*
7. Latanoprostene bunod (LBN) contains what important new molecule?*
8. Nitric Oxide lowers IOP by?*
9. The peak IOP reduction of latanoprostene bunod (LBN) in the Apollo Study was?*
10. The Voyager study demonstrated what percent IOP reduction for LBN from mean baseline IOP?*
11. The most common Adverse Reaction to LBN in the Apollo and Lunar Studies was?*
12. The Jupiter Study demonstrated what mean percent reduction of IOP from a baseline of 19.6mmHg?*
13. Sleep laboratory studies have found that LBN has what effect during the nocturnal time period?*
14. Approximately what percent of open angle glaucoma in the USA is the ā€œnormal tensionā€ variety?*
15. A recent (2022) independent research publication found that glaucoma and ocular hypertensive subjects treated with LBN for four had what finding?*
16. Netarsudil’s primary location of action on IOP reduction is?*
17. Netarsudil is an inhibitor of?*
18. The mean decrease of IOP by netarsudil in the Rocket studies was?*
19. Ocular side effects of netarsudil include each of the following EXCEPT?*
20. Which glaucoma medication is now available in a preservative free (PF) formulation?*

Personal Information

Name*
Address*

Payment Information

After 90 days, pricing will increase to $30.
This course was presented over 90 days ago. Due to this late submission of TQ, your TQ credit price is $30.
This field is hidden when viewing the form

Course Information (HIDDEN)

This field is hidden when viewing the form
This field is hidden when viewing the form
This field is hidden when viewing the form
Do not include ending backslash (aka no .com/)
This field is hidden when viewing the form

Submit a Comment Cancel reply

Your email address will not be published. Required fields are marked *

Upcoming Conferences

Ready to get away this summer or fall. View our upcoming conferences and register today!

View

Case Challenges

Case Challenges

View our library of case challenges and share your comments or questions in the comment box below!

Learn More
For questions and more information, please contact usĀ at events@optometricedu.com

Like and follow us on Facebook, Twitter, and Instagram for conference updates!

Subscribe For Event Updates

* indicates required
  • Home
  • Cookie Policy
  • Privacy Policy
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}